Repurposing alpha1 Noradrenergic Antagonists for Alcoholism Treatment
Completed · Phase 1/Phase 2 · Has a placebo group
Conditions studied: Alcoholism
In brief
Double-blind, placebo-controlled, cross-over design study examining the effects of a norepinephrine alpha1 receptor antagonist (prazosin) on stress reactivity in a laboratory stressor task.
Key facts
- Study ID
- NCT02966340
- Run by
- University of Wisconsin, Madison
- People needed
- 70
- Starts
- 2016-11-01
- Expected to finish
- 2018-03-12
- Last updated by the study team
- 2019-05-28
Who can join
Age: 18 and older, up to 50. Sex: any. Healthy volunteers: accepted.
Where it is running
- University of Wisconsin — Madison, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.